Cargando…
Retrospective evaluation of toceranib phosphate (Palladia®) use in the treatment of inoperable, metastatic, or recurrent canine pheochromocytomas: 5 dogs (2014–2017)
BACKGROUND: Effective treatment options for inoperable, metastatic, or recurrent canine pheochromocytomas are lacking. In humans, specific germline mutations exist that drive the development of pheochromocytomas. Pharmaceutical blockade of these abnormalities with small molecule inhibitors are an ef...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6122699/ https://www.ncbi.nlm.nih.gov/pubmed/30176869 http://dx.doi.org/10.1186/s12917-018-1597-7 |
_version_ | 1783352706126053376 |
---|---|
author | Musser, Margaret L. Taikowski, Kathryn L. Johannes, Chad M. Bergman, Philip J. |
author_facet | Musser, Margaret L. Taikowski, Kathryn L. Johannes, Chad M. Bergman, Philip J. |
author_sort | Musser, Margaret L. |
collection | PubMed |
description | BACKGROUND: Effective treatment options for inoperable, metastatic, or recurrent canine pheochromocytomas are lacking. In humans, specific germline mutations exist that drive the development of pheochromocytomas. Pharmaceutical blockade of these abnormalities with small molecule inhibitors are an effective treatment strategy. Similar mutations may exist in the dog, and thus, treatment with similar small molecule inhibitors may provide a survival advantage. The purpose of this study was to assess the role of toceranib phosphate in the treatment of inoperable, metastatic, or recurrent canine pheochromocytomas. RESULTS: Retrospectively, medical records of dogs that had a diagnosis or suspect diagnosis of a pheochromocytoma were reviewed for information regarding response to toceranib phosphate and overall outcome. Five dogs were identified that fit the inclusion criteria. All five experienced clinical benefit (1 partial response, 4 stable disease). Progression-free interval (PFI) for the dog with the partial response was 61 weeks. PFI for the two dogs with stable measurable disease were 36 weeks and 28 weeks. PFI in the two dogs with stable metastatic disease were at least 11 weeks and 18 weeks. CONCLUSIONS: Based on this limited series of dogs, the results suggest that toceranib may have biological activity in dogs with primary and metastatic pheochromocytomas. Larger studies are needed to define the use and response to toceranib in dogs with gross, microscopic, and metastatic pheochromocytoma. |
format | Online Article Text |
id | pubmed-6122699 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-61226992018-09-10 Retrospective evaluation of toceranib phosphate (Palladia®) use in the treatment of inoperable, metastatic, or recurrent canine pheochromocytomas: 5 dogs (2014–2017) Musser, Margaret L. Taikowski, Kathryn L. Johannes, Chad M. Bergman, Philip J. BMC Vet Res Research Article BACKGROUND: Effective treatment options for inoperable, metastatic, or recurrent canine pheochromocytomas are lacking. In humans, specific germline mutations exist that drive the development of pheochromocytomas. Pharmaceutical blockade of these abnormalities with small molecule inhibitors are an effective treatment strategy. Similar mutations may exist in the dog, and thus, treatment with similar small molecule inhibitors may provide a survival advantage. The purpose of this study was to assess the role of toceranib phosphate in the treatment of inoperable, metastatic, or recurrent canine pheochromocytomas. RESULTS: Retrospectively, medical records of dogs that had a diagnosis or suspect diagnosis of a pheochromocytoma were reviewed for information regarding response to toceranib phosphate and overall outcome. Five dogs were identified that fit the inclusion criteria. All five experienced clinical benefit (1 partial response, 4 stable disease). Progression-free interval (PFI) for the dog with the partial response was 61 weeks. PFI for the two dogs with stable measurable disease were 36 weeks and 28 weeks. PFI in the two dogs with stable metastatic disease were at least 11 weeks and 18 weeks. CONCLUSIONS: Based on this limited series of dogs, the results suggest that toceranib may have biological activity in dogs with primary and metastatic pheochromocytomas. Larger studies are needed to define the use and response to toceranib in dogs with gross, microscopic, and metastatic pheochromocytoma. BioMed Central 2018-09-03 /pmc/articles/PMC6122699/ /pubmed/30176869 http://dx.doi.org/10.1186/s12917-018-1597-7 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Musser, Margaret L. Taikowski, Kathryn L. Johannes, Chad M. Bergman, Philip J. Retrospective evaluation of toceranib phosphate (Palladia®) use in the treatment of inoperable, metastatic, or recurrent canine pheochromocytomas: 5 dogs (2014–2017) |
title | Retrospective evaluation of toceranib phosphate (Palladia®) use in the treatment of inoperable, metastatic, or recurrent canine pheochromocytomas: 5 dogs (2014–2017) |
title_full | Retrospective evaluation of toceranib phosphate (Palladia®) use in the treatment of inoperable, metastatic, or recurrent canine pheochromocytomas: 5 dogs (2014–2017) |
title_fullStr | Retrospective evaluation of toceranib phosphate (Palladia®) use in the treatment of inoperable, metastatic, or recurrent canine pheochromocytomas: 5 dogs (2014–2017) |
title_full_unstemmed | Retrospective evaluation of toceranib phosphate (Palladia®) use in the treatment of inoperable, metastatic, or recurrent canine pheochromocytomas: 5 dogs (2014–2017) |
title_short | Retrospective evaluation of toceranib phosphate (Palladia®) use in the treatment of inoperable, metastatic, or recurrent canine pheochromocytomas: 5 dogs (2014–2017) |
title_sort | retrospective evaluation of toceranib phosphate (palladia®) use in the treatment of inoperable, metastatic, or recurrent canine pheochromocytomas: 5 dogs (2014–2017) |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6122699/ https://www.ncbi.nlm.nih.gov/pubmed/30176869 http://dx.doi.org/10.1186/s12917-018-1597-7 |
work_keys_str_mv | AT mussermargaretl retrospectiveevaluationoftoceranibphosphatepalladiauseinthetreatmentofinoperablemetastaticorrecurrentcaninepheochromocytomas5dogs20142017 AT taikowskikathrynl retrospectiveevaluationoftoceranibphosphatepalladiauseinthetreatmentofinoperablemetastaticorrecurrentcaninepheochromocytomas5dogs20142017 AT johanneschadm retrospectiveevaluationoftoceranibphosphatepalladiauseinthetreatmentofinoperablemetastaticorrecurrentcaninepheochromocytomas5dogs20142017 AT bergmanphilipj retrospectiveevaluationoftoceranibphosphatepalladiauseinthetreatmentofinoperablemetastaticorrecurrentcaninepheochromocytomas5dogs20142017 |